A phase I/II trial to investigate Imprime PGG (PGG glucan) in combination with monoclonal antibody (MAb) therapies in rituximab-refractory follicular lymphoma

Trial Profile

A phase I/II trial to investigate Imprime PGG (PGG glucan) in combination with monoclonal antibody (MAb) therapies in rituximab-refractory follicular lymphoma

Planning
Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2015

At a glance

  • Drugs PGG-glucan (Primary)
  • Indications Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top